3-(Aminomethyl)piperazine-2,5-dione as a novel NMDA glycine site inhibitor from the chemical universe database GDB

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 14, 2009, Pages 3832-3835

  Nguyen, Kong Thong ^a   Luethi, Erika ^a   Syed, Salahuddin ^a   Urwyler, Stephan ^a   Bertrand, Sonia ^b   Bertrand, Daniel ^b   Reymond, Jean Louis ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b Medical Faculty   (Switzerland)

Author keywords

Diketopiperazine; Docking; Glutamate receptors; Neurochemistry; Virtual screening

Indexed keywords

3 (AMINOMETHYL)PIPERAZINE 2,5 DIONE; 5 (AMINOMETHYL)PIPERAZINE 2,3 DIONE; GLUTAMATE RECEPTOR; GLUTAMIC ACID; GLYCINE; LIGAND; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; PIPERAZINEDIONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHEMICAL STRUCTURE; DRUG TARGETING; LEARNING; MEMORY; MOLECULAR DOCKING; NERVE CELL PLASTICITY; NEUROCHEMISTRY; NONHUMAN; OOCYTE; STEREOISOMERISM; SYNTHESIS; XENOPUS;

ANIMALS; BINDING SITES; COMPUTER SIMULATION; DATABASES, FACTUAL; DIKETOPIPERAZINES; GLYCINE; OOCYTES; RECEPTORS, N-METHYL-D-ASPARTATE; SOFTWARE; THERMODYNAMICS; XENOPUS LAEVIS;

EID: 67649654027     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.04.021     Document Type: Article

References (27)

1. Bleicher K.H., Böhm H.-J., Müller K., and Alanine A.I. Nat. Rev. Drug Disc. 2 (2003) 369
2. Fink T., Bruggesser H., and Reymond J.-L. Angew. Chem., Int. Ed. 44 (2005) 1504
3. Fink T., and Reymond J.-L. J. Chem. Inf. Model. 47 (2007) 342
4. Nguyen K.T., Syed S., Urwyler S., Bertrand S., Bertrand D., and Reymond J.-L. ChemMedChem 3 (2008) 1520
5. Smart T.G. Curr. Opin. Neurobiol. 7 (1997) 358
6. Choi D.W., and Rothman S.M. Annu. Rev. Neurosci. 13 (1990) 171
7. Olney J.W. Annu. Rev. Pharmacol. Toxicol. 30 (1990) 47
8. Olney J.W., Labruyere J., Wang G., Wozniak D.F., Price M.T., and Sesma M.A. Science 254 (1991) 1515
9. Kemp J.A., and McKernan R.M. Nat. Neurosci. (2002) 1039
10. Franks G.P. Nat. Rev. Neurosci. 9 (2008) 370
11. Kleckner N.W., and Dingledine R. Science 241 (1988) 835
12. Hood W.F., Compton R.P., and Monahan J.B. Neurosci. Lett. 98 (1989) 91
13. Watson G.B., and Lanthorn T.H. Neuropharmacology 29 (1990) 727
14. Warren G.L., Andrews C.W., Capelli A.-M., Clarke B., LaLonde J., Lambert M.H., Lindvall M., Nevins N., Semus S.F., Senger S., Tedesco G., Wall I.D., Woolven J.M., Peishoff C.E., and Head M.S. J. Med. Chem. 49 (2006) 5912
15. Hawkins P.C.D., Skillman A.G., and Nicholls A. J. Med. Chem. 50 (2007) 74
16. Sadowski J., and Gasteiger J. Chem. Rev. 93 (2003) 2567
17. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., and Olson A.J. J. Comput. Chem. 19 (1998) 1639
18. Bender A., Mussa H.Y., Glen R.C., and Reiling S. J. Chem. Inf. Comput. Sci. 44 (2004) 170
19. Waki M., Kitajima Y., and Izumiya N. Synthesis (1981) 266
20. Loudon M.G., Radhakrishna A.S., Almond M.R., Blodgett J.K., and Boutin R.H. J. Org. Chem. 49 (1984) 4272
21. Compound 7 has been previously reported from peptide coupling between glycine methyl ester and 3-Boc-l-2,3-diaminopropanoic acid. Hassall C.H., Tyson R.G., and Chexal K.K. J. Chem. Soc., Perkin Trans. 1 (1976) 2010
22. Akiyama M., Katoh A., and Tsuchiya Y. J. Chem. Soc., Perkin Trans. 1 (1989) 235
23. Benoist E., Loussouarn A., Remaud P., Chatal J.-F., and Gestin J.-F. Synthesis (1998) 1113
24. D for glycine is approximately 0.15 μM. See:. Johnson J.W., and Ascher P. J. Physiol. 455 (1992) 339
25. Cheng Y.C., and Prusoff W.H. Biochem. Pharmacol. 22 (1973) 3099
26. Hopkins A.L., Groom C.R., and Alex A. Drug Discovery Today 9 (2004) 430
27. Furukawa H., and Gouaux E. EMBO J. 22 (2003) 2873